cultivator for sale alberta

Tinley's Announces Q3 2021 Results and Provides Corporate Updates

 

The Tinley Beverage Company Inc. (CSE:TNY; OTC:TNYBF) ("Tinley's" or the "Company") is pleased to provide corporate updates to coincide with the release today of the Company's condensed interim consolidated financial statements and management's discussion and analysis thereon for the three and nine months ended September 30, 2021, which are accessible under the Company's profile on SEDAR at www.sedar.com .

 

   Third Quarter 2021 Financial Highlights   

 

The following information compares certain financial results of the Company for the three months ended September 30, 2021 against the same period in 2020:

 
  • Sales of $198,165 in 2021, compared to $34,628 in 2020, representing an increase of 472%;
  •  
  • Gross margin profit of $28,234 in 2021, compared to a gross margin loss of $65,795 in 2020;
  •  
  • Comprehensive loss of $2,021,029 in 2021, compared to comprehensive loss or $2,224,034 in 2020, representing an improvement, or reduction in loss of $203,005; and
  •  
  • The comprehensive loss amount included non-cash share-based payments of $207,056, compared to $236,607 in 2020.
  •  

   Management Statement: Review Refocus and Redirect for Revenue and Value Creation   

 

"The Company has undergone significant changes in the final weeks of Q3 2021, with the resignation of our CEO and appointment of a new CFO," said Ted Zittell, Rick Gillis, and Doug Fulton, members of the Office of the CEO said in a joint statement issued to coincide with the Q3 2021 results released today. The statement continues: "Executive leadership, in close collaboration with the board and management, have been actively engaged in reviewing operations and client opportunities. We are working to provide clear direction, enhanced planning, and fresh focus on assets, systems, and resources. Management is committed to ensure we remain in continuous supply of Tinley's™ brand products in California. The Company is actively pursuing listings, production and launch of Tinleys™ infused products in Canada, and we are focused on high-volume and category-expanding brands for Lakewood's contract manufacturing operations at our Long Beach facility. We are strategically investing in high-demand and anticipated high-return capabilities and resources for our California operations to meet an expanded range of current and new contract manufacturing client product requirements. All efforts are focused on growing revenue and driving operating efficiencies. The Office of the CEO and the board will work to provide timely updates on progress though the month of December 2021 and throughout the year ahead."

 

  The Company will conduct an online tour of its Long Beach facility, followed by a moderated online Q&A session with ‘Co-CEO's' Rick Gillis, Doug Fulton and Ted Zittell, on Wednesday December 1, 2021 at 10am PST/1:00pm EST for approximately one hour. To join the session, go to    www.instagram.com/drinktinleys    and see our "Live Story".  

 

   Operations Update   

 

  Long Beach Facility Distribution Licence  

 

As previously announced, Lakewood Libations, Inc. ("Lakewood") received its provisional Cannabis Distribution licence issued by the Department of Cannabis Control ("DCC") of the State of California, which licence will become operational following final inspections and sign-off of permits by the City of Long Beach ("City"). Also as previously announced, the Company has entered into a purchase agreement to acquire all of the equity interests in Lakewood, the closing of which is subject to certain standard conditions precedent including applicable regulatory approvals.

 

As of November 26, 2021, the City has completed final permit inspections relating to Lakewood's distribution licence applications. The issuance of the business licence and permit to occupy and operate in the state-licensed distribution space is now expected in or around the second week of December 2021. As soon as possible following activation of the business licence by the City, Lakewood plans to begin transferring newly manufactured own-brand and client contract manufactured product batches from the adjacent licensed manufacturing space to the licensed distribution area to accelerate sampling and state testing, and to improve time frames for fulfillment to licensed retailers and home delivery channels.

 

  Client Production at Tinley's Long Beach Facility  

 

The Company has planned contract manufacturing production at its Lakewood facility in Long Beach, CA through the end of November and into December, which is expected to fulfill service requests for both new and repeat client-brand products. The Company's Q4 revenue is anticipated to include fees from new and previously signed client agreements, as well as initial client fees to be paid in connection with service requests from contract manufacturing clients scheduled to be completed in Q1 2022.

 

  Tinley's Own Brand Production at Tinley's Long Beach Facility  

 

Following the lack of supply of the Company's products at certain dispensaries due to supply chain and distribution delays, the Company has taken steps to address these issues and new production runs of Tinley's™ '27 and Tinley's™ Tonics products are scheduled for December 2021 and January 2022 to meet current and forecast demand. The Company is working with Hard Car Distribution to manage timely delivery to licensed dispensaries and the home delivery channels, as well as to collaborate on enhanced inventory and sales reporting.

 

  Tinley's Long Beach Facility Enhancements to Potentially Unlock Revenue and Efficiency  

 

In addition to the previously announced project to engineer and install an enhanced mini-bottle line to increase efficiency, versatility and capacity around the high-demand mini bottle format, the Company is currently working with third-party specialist resources to plan and implement critical paths for additional capabilities expected to come online in Q1 and Q2 2022. These include additional micro and yeast kill steps, and inert gas drip fill options, planned in response to growing demand for these capabilities from both current and new contract manufacturing clients. Client and own-brand production activity is timed around facility capability enhancements and equipment installations and upgrades, to run concurrently as possible. The Company expects that the previously announced closed-loop non-alcoholic beer intake and infusion process, commissioning of the can line, and commercial calibration of the tunnel pasteurizer for high-demand container formats will be completed and available for client production scheduling on or around mid-December. All upgrades, new equipment and new processes are designed for optimal integration into the facility's existing batching, holding, filling and post-fill secondary packaging lines and palletizing functions.

 

  Beckett's  

 

The Company is actively reviewing strategic opportunities to realize increased value from Beckett's inventory and assets in both Canada and the US without capital investment.

 

  Canadian Infused Tinleys™   : Path to Production and Sales  

 

The Company, through its sales agent and with the support of its two licensed Canadian contract manufacturers, delivered a preliminary submission for Tinleys™ infused products to the Ontario Cannabis Store ("OCS") and was invited to make a final submission for the scheduled April 2022 product release which was delivered on November 23, 2021. The OCS has indicated that it is currently considering approval of the Company's products, and that approved products will be announced in mid-December 2021. The Company's products may be available for purchase in the OSC in April 2022. There can be no assurance that the OSC will accept the Company's products for resale.

 

On November 26, 2021, the Company presented a formal submission to the cannabis drinks buyer at the Alberta Gaming and Liquor Commission ("AGLC"). Additionally, the Company is working with its sales agent to schedule a presentation for submission to British Columbia Liquor Distribution Branch by mid-December 2021. General supply chain constraints and specific weather-related delays in British Columbia may delay production of Tinley's Classics until mid-January in British Columbia.

 

    About The Tinley Beverage Company and Beckett's Tonics    

 

 The Tinley Beverage Company Inc. (CSE:TNY; OTC:TNYBF) develops and has licensed the production through its Long Beach, CA state-licensed manufacturing facility terpene and cannabis-infused non-alcoholic Tinley's™ '27 and Tinley's™ Classics products which are distributed to licensed dispensaries and home delivery channels in California. Expansion of these products, adapted for manufacturing and sale in Canada, is currently underway. The Beckett's Classics™ and Beckett's ‘27™ lines of non-alcoholic, terpene-infused non-cannabis versions of these formulations are available in select mainstream food, beverage, and specialty retailers, as well as online, in the United States as well as in select grocery and specialty stores in Canada. Tinley's facility in Long Beach California contains some of the state's most versatile and technologically advanced cannabis-licensed beverage manufacturing equipment and provides manufacturing services for third-party brands in addition to producing Company-owned brands. Please visit www.drinktinley.com , and www.drinkbecketts.com Twitter and Instagram (@drinktinleys and @drinkbecketts) for recipes, product information and home delivery options.

 

    Forward-Looking Statements    

 

This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and statements regarding the Company's expectations with respect to the future business, operations, expansion to additional jurisdictions, consumer loyalty, anticipated consumer demand, expanded consumer interest in cannabis infused beverages and overall category growth, the closing of the acquisition of Lakewood, the timing of Lakewood's business licence and permit to occupy, timing of production runs, regulatory approval by the OSC, the AGLC and the BC regulator of Tinley's infused products, revenue growth, management's expectations regarding growth, phrases containing words such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental, or other project approvals, political risks, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices and delays in the development of projects. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. Readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by law. Products, formulations, and timelines outlined herein are subject to change at any time.

 

For further information, please contact:

 

 The Tinley Beverage Company Inc.
Ted Zittell
(310) 507-9146
relations@drinktinley.com
Twitter: @drinktinleys and @drinkbecketts
Instagram: @drinktinleys and @drinkbecketts
www.drinktinley.com  

 

 CSE:TNY; OTC:TNYBF

 


  

 

 

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Closeup of lush green cannabis leaves.

Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout

Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.

The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.

The country’s Ministry of Public Health issued an order this week stating that cannabis only be sold with a medical prescription, effectively ending a short-lived era of liberal recreational access.

Keep reading...Show less
Cannabis leaf over map of Australia.

A State-by-State Guide to Cannabis in Australia

Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.

Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will reach AU$3.73 billion in 2024 and grow at an annual rate of 3.22 percent, culminating in market volume worth AU$4.53 billion by 2029.

However, Australia’s cannabis industry is still young. Despite there being a strong case for a regulated market, which was outlined in a July 2024 report by the Penington Institute, recreational use is not legal and medical access remains limited and regulated.

Keep reading...Show less
Cannabis leaf on road marked with "2025," with sunlight in the background.

New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025

Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve.

Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among younger users, and cannabis companies are adapting their offerings to meet shifting demand.

Meanwhile, regulatory uncertainty, particularly surrounding the future of the US Farm Bill and state-level restrictions on hemp-derived cannabinoids, continues to challenge the market.

Despite these headwinds, production data and long-term growth forecasts suggest the cannabis industry remains on a promising — albeit turbulent — path. Read on for more on key trends to watch in 2025.

Consumption methods evolving post-legalization

Shifts in consumer behavior are reshaping markets across the board, and the cannabis industry is no exception.

While smoking remains the dominant method of cannabis consumption, a recent report from the Centers for Disease Control and Prevention highlights the growing popularity of edibles, vaping and dabbing.

The report notes that vaping and dabbing are particularly pronounced among younger adults.

A separate study published by the American Medical Association and funded in part by the Canadian Institutes of Health Research also points to how product preferences have changed among Canadian users since legalization in 2018.


The study indicates that while the use of flower, cannabis concentrates, oil, tinctures and topicals has decreased during that time, the use of vape cartridges, edibles and beverages has increased.

Edibles and beverages were legalized in Canada in late 2019, and Truss Beverage was one of the first players to introduce cannabis-infused drinks. Truss was a joint venture formed by Molson Coors Canada (TSX:TPX.A,TSX:TPX.B) and HEXO, a cannabis company that has since been acquired by Tilray Brands (TSX:TLRY,NASDAQ:TLRY).

In early 2020, Tilray launched a lineup of confectionery, wellness products and beverages through its subsidiary, High Park; Canopy Growth (TSX:WEED,NASDAQ:CGC) made a similar move. These companies gradually brought their products to the US as more states legalized cannabis for medical and/or recreational use.

Today, established cannabis brands typically offer edibles and beverages alongside their other products. Organigram Global (TSX:OGI,NASDAQ:OGI) is one of the newest US entrants, with its April acquisition of Collective Project providing immediate access to the US hemp-derived THC beverage market.

Growing awareness of health and wellness, potentially amplified by the pandemic-led adoption of health trackers, appears to be making an impact on the alcoholic beverage market.

A 2023 Gallup poll reveals a two decade decline in alcohol consumption, particularly among younger adults, suggesting a shift towards more health-conscious lifestyles within this demographic.

Craft beer production declined by 4 percent year-on-year in 2024, according to data collected by the Brewers Association. This marked the largest drop in the industry's history, excluding the pandemic. For small, independent craft breweries, 2024 marked the third consecutive year of declining production. A drop in the number of operating small breweries last year provides further evidence of this trend, with 501 closures in 2024 versus 434 openings.

Challenges in the alcohol market extend beyond the brewing industry, with the New York Times recently reporting the closure of a handful of nightclubs facing decreased alcohol sales alongside rising insurance and rent costs.

Meanwhile, cannabis lounges have been popping up across the US for the last several years. As of early 2025, several states had legalized or were in the process of implementing regulations for cannabis consumption lounges.

Hemp market growth despite regulatory uncertainty

The burgeoning hemp industry is another segment of the expanding cannabis market.

The legalization of industrial hemp — defined as cannabis with a THC concentration of 0.3 percent or less — through the 2018 Farm Bill led to initial investment and optimistic projections for CBD wellness products and various industrial applications. The sector’s rapid evolution also brought the rise of hemp-derived intoxicating cannabinoids, creating a market that presented both opportunities and complexities for participants.

However, after an initial boom, a lack of infrastructure and clearly defined regulations for CBD, as well as state-level variations and market oversupply, ultimately contributed to a quick retraction.

2024 was a pivotal year for the US hemp industry, as the hemp-related provisions of the 2018 Farm Bill — originally set to expire in September 2023, but extended to December 31, 2024 — created an urgent need to address critical issues like THC limits and the regulation of novel hemp-derived cannabinoids. A major point of contention was the proposed shift from defining hemp based on Delta-9 THC concentration (0.3 percent or less) to “total THC,” which includes THCA.

This change had the potential to significantly impact farmers and processors, as many hemp varieties that are compliant under the Delta-9 THC rule could exceed the 0.3 percent limit when THCA is included.

Various bills and amendments were proposed in 2024 as part of the Farm Bill discussions, each with different approaches to regulating hemp. Separate regulatory frameworks for industrial hemp and hemp grown for cannabinoids were suggested, and many states took their own action, leading to a patchwork of regulations and even outright bans.

Despite challenges, data from the US Department of Agriculture suggests signs of recovery.

The department's annual National Hemp Report from 2024 points to an 18 percent increase in industrial hemp production value between 2022 and 2023, with output growth seen in specific sectors like floral (18 percent), fiber (133 percent) and seed hemp (414 percent). The 2025 report from the Department of Agriculture indicates further expansion, with notable increases observed in both acreage (up 64 percent from 2023) and value (46 percent).

The 2024 Farm Bill ultimately did not pass, and right now the hemp industry is operating under a temporary extension of the 2018 Farm Bill under the American Relief Act of 2025, signed into law on December 21, 2024.

The 2018 Farm Bill is now set to expire on September 30, 2025.

While analysts for Markets and Markets project that the North American hemp industry will grow at a CAGR of 22.4 percent and ultimately reach a valuation of US$30.24 billion by 2029, the future of the industry will be heavily influenced by the outcome of the ongoing Farm Bill discussions.

US cannabis legalization remains stalled

Although there is clear demand for cannabis products, the now-defunct rescheduling process in the US is likely to continue casting a shadow of uncertainty over the industry's long-term trajectory.

Legal and procedural delays, including allegations of improper conduct and bias within the US Drug Enforcement Administration (DEA), led to hearing cancellations, and the new administration of US President Donald Trump has brought leadership changes to key agencies like the DEA and the Department of Justice.

Terry Cole, who Trump nominated to be DEA administrator on February 11, has a history of opposing cannabis legalization in the country. Similarly, Pam Bondi, Trump’s pick to lead the justice department, staunchly opposed a movement to legalize medical cannabis during her tenure as Florida’s attorney general.

While there have been bipartisan efforts in Congress to end federal cannabis prohibition and establish regulations for eventual legalization, the DEA’s actions and statements indicate a potential stall or reversal of progress.

In addition to that, new research is adding complexity to the debate.

A study published in the American Journal of Psychiatry this past March highlights an association between the use of high-potency cannabis strains and increased risks of psychosis, a factor that may not have been fully considered by the Department of Health and Human Services. As stronger cannabis strains become more widely available, a reassessment of their potential health risks may be required.

Investor takeaway

While the cannabis industry holds promise for growth and innovation, investors must remain acutely aware of the regulatory uncertainties and market volatility that will undoubtedly shape its trajectory in the years to come.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

Person touching a cannabis plant; Australia map in flag colours.

ASX Cannabis Stocks: 10 Biggest Companies

While Australia has yet to legalise all forms of cannabis, the country is a growing medical cannabis and hemp market, with many companies manufacturing, researching and exporting the plant-based product.

Medical cannabis was federally legalised in 2016, and the export of cannabis from Australia was legalised in 2018. As for recreational use, the only state to legalise recreational use and possession so far is the Australian Capital Territory, which did so in 2020, but it did not establish a regulated recreational cannabis market.

The country's medical cannabis market has been steadily expanding in size and scope. A Penington Institute report shows that Australians spent approximately AU$400 million on medicinal cannabis in the first half of 2024, 72 percent higher than the AU$234 million they spent over the entirety of 2022.

Keep reading...Show less
Cannabis leaves, gavel.

Cannabis Round-Up: Rescheduling Faces New Roadblocks, SAFER Banking Act Gets Another Look

February 2025 was characterized by an evolving legislative landscape and important financial updates from major players.

These developments underscore the complex and dynamic nature of the sector as it continues to navigate legal, financial, and regulatory challenges while experiencing ongoing growth and evolution.

Discussions around cannabis rescheduling, changes in federal agency leadership, state-level legalization efforts, and financial reports from key companies all contributed to a month of notable activity in the cannabis space.

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: Banking Reform and Rescheduling De-Prioritized as Trump Takes Office

As a new year began, the cannabis industry saw a range of impactful events in January.

Legal obstacles continued to impede progress on a once-promising attempt to reschedule cannabis in the US, and President Donald Trump's leadership choices for key agencies are diminishing hopes it can be accomplished.

Meanwhile, cannabis banking reform won't be discussed at Wednesday's (February 5) meeting of the Standing Senate Committee on Banking, Commerce and the Economy, and Congress seems in no rush to address it.

Keep reading...Show less

Latest Press Releases

Related News

×